This site is intended for U.S. healthcare professionals.

See Full Prescribing Information | Important Safety Information

YCANTH™, the FDA-approved in-office treatment for molluscum contagiosum in patients 2+, is available.
Fill out our survey to see if you qualify to become a YCANTH prescriber.

About The Drug

YCANTH is an FDA-approved topical solution (cantharidin) 0.7% for the treatment of molluscum contagiosum. It is approved for use on adults, and pediatric patients two years of age and older.1

What Are The Benefits?

  • Reduces disease progression and transmission, including autoinoculation
  • Reduces discomfort and itching
  • May help alleviate anxiety in caregivers
  • Prevents exacerbations of comorbidities, such as atopic dermatitis, and may help prevent bacterial infections
  • May reduce the negative impacts on quality of life due to scarring, bullying, and exclusion from activities
YCANTH Defines The Treatment Experience

YCANTH Defines The Treatment Experience

Complete-The-Survey
YCANTH is easily applied in the office using the small-tip applicator, apply only enough to cover each lesion 1* Additionally, avoid application near the eyes and mucosal tissues, and to adjacent healthy skin. If YCANTH comes in contact with healthy skin during application, it should be removed with a cotton swab or gauze.
Schedule-An-Appointment

It may be administered every 3 weeks as needed, and applied only to lesions that are practically and medically safe to treat. YCANTH should be removed with soap and water 24 hours after treatment. If severe blistering, severe pain, or other adverse reactions occur, remove YCANTH prior to the recommended 24 hours after administration. Do not cover treated lesions with bandages.1

Repeat every three weeks in-office until bumps have cleared,
YCANTH is a vesicant. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH. No serious adverse reactions were reported in clinical trials.

The solution is clear — and so is patients’ skin. Take our brief survey to see if you are a good fit to join other prescribers already helping to tackle molluscum.

See If You Qualify

1: https://verrica.com/pi/ycanth
2: Silverberg NB. Cutis. 2019;104(5):301-305.
3: American Academy of Pediatrics. Red Book. 2021:535-537
4: van der Wouden JC, et al. Cochrane Database Syst Rev. 2017;5:CD004767

Learn more about how to become a YCANTH prescriber and help get patients the relief they need.
Become a Prescriber
.